Literature DB >> 26645827

Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow".

Samer Tabchi1, Marwan Ghosn2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26645827     DOI： 10.1007/s11523-015-0406-5

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  7 in total

1.  Comment on: "Regorafenib: Start Low and Go Slow".

Authors:  Christelle de la Fouchardière
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

2.  Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.

Authors:  Axel Grothey
Journal:  Clin Adv Hematol Oncol       Date:  2015-08

Review 3.  Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events.

Authors:  Ralf-Dieter Hofheinz; Dirk Arnold; Stefan Kubicka; Nicole Prasnikar; Arndt Vogel
Journal:  Oncol Res Treat       Date:  2015-05-12       Impact factor: 2.825

4.  Regorafenib: start low and go slow.

Authors:  S Tabchi; M Ghosn
Journal:  Target Oncol       Date:  2014-12-30       Impact factor: 4.493

5.  A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

Authors:  Klaus Mross; Annette Frost; Simone Steinbild; Susanne Hedbom; Martin Büchert; Ulrike Fasol; Clemens Unger; Jörn Krätzschmar; Roland Heinig; Oliver Boix; Olaf Christensen
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

6.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

7.  Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.

Authors:  Daniel J Sargent; Claus Henning Köhne; Hanna Kelly Sanoff; Brian M Bot; Matthew T Seymour; Aimery de Gramont; Ranier Porschen; Leonard B Saltz; Philippe Rougier; Christopher Tournigand; Jean-Yves Douillard; Richard J Stephens; Axel Grothey; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.